DK1838318T3 - Anvendelse af oxycodon til behandling af visceral smerte - Google Patents

Anvendelse af oxycodon til behandling af visceral smerte

Info

Publication number
DK1838318T3
DK1838318T3 DK06700652T DK06700652T DK1838318T3 DK 1838318 T3 DK1838318 T3 DK 1838318T3 DK 06700652 T DK06700652 T DK 06700652T DK 06700652 T DK06700652 T DK 06700652T DK 1838318 T3 DK1838318 T3 DK 1838318T3
Authority
DK
Denmark
Prior art keywords
oxycodone
treatment
visceral pain
visceral
pain
Prior art date
Application number
DK06700652T
Other languages
Danish (da)
English (en)
Inventor
Asbjorn Mohr Drewes
Lars Arendt Nielsen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35871217&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1838318(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Application granted granted Critical
Publication of DK1838318T3 publication Critical patent/DK1838318T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
DK06700652T 2005-01-18 2006-01-17 Anvendelse af oxycodon til behandling af visceral smerte DK1838318T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64549005P 2005-01-18 2005-01-18
PCT/EP2006/050252 WO2006077212A1 (en) 2005-01-18 2006-01-17 Use of oxycodone for treating visceral pain

Publications (1)

Publication Number Publication Date
DK1838318T3 true DK1838318T3 (da) 2010-01-04

Family

ID=35871217

Family Applications (2)

Application Number Title Priority Date Filing Date
DK06700652T DK1838318T3 (da) 2005-01-18 2006-01-17 Anvendelse af oxycodon til behandling af visceral smerte
DK200700207U DK200700207U3 (da) 2005-01-18 2007-07-24 Anvendelse af oxycodon til behandling af visceral smerte

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200700207U DK200700207U3 (da) 2005-01-18 2007-07-24 Anvendelse af oxycodon til behandling af visceral smerte

Country Status (31)

Country Link
US (2) US20080200493A1 (enExample)
EP (1) EP1838318B1 (enExample)
JP (1) JP5049139B2 (enExample)
KR (10) KR20200128451A (enExample)
CN (1) CN101106996B (enExample)
AP (1) AP2249A (enExample)
AR (1) AR052880A1 (enExample)
AT (2) ATE446092T1 (enExample)
AU (1) AU2006207498B2 (enExample)
BR (1) BRPI0606247A2 (enExample)
CA (1) CA2595043C (enExample)
CY (1) CY1109660T1 (enExample)
DE (2) DE602006009899D1 (enExample)
DK (2) DK1838318T3 (enExample)
EA (1) EA013544B1 (enExample)
ES (1) ES2333901T3 (enExample)
HR (1) HRP20090679T1 (enExample)
IL (1) IL184530A (enExample)
ME (1) ME01066B (enExample)
MX (1) MX2007007207A (enExample)
MY (1) MY144471A (enExample)
NO (1) NO338968B1 (enExample)
NZ (1) NZ555852A (enExample)
PL (1) PL1838318T3 (enExample)
PT (1) PT1838318E (enExample)
RS (1) RS51069B (enExample)
SI (1) SI1838318T1 (enExample)
TW (1) TWI432196B (enExample)
UA (1) UA85471C2 (enExample)
WO (1) WO2006077212A1 (enExample)
ZA (1) ZA200705231B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3045182T3 (en) 2005-11-14 2018-03-19 Teva Pharmaceuticals Int Gmbh ANTAGONIST ANTIBODIES AGAINST CALCITONIN GEN-RELATED PEPTIDE TO TREAT HEAT
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009109911A1 (en) 2008-03-04 2009-09-11 Pfizer Limited Methods of treating chronic pain
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
EP2445487A2 (en) 2009-06-24 2012-05-02 Egalet Ltd. Controlled release formulations
RU2535074C2 (ru) * 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Способы лечения висцеральной боли путем введения антител-антагонистов, направленных против пептида, связанного с геном кальцитонина
TWI692485B (zh) 2011-05-20 2020-05-01 美商艾爾德生物控股有限責任公司 抗降血鈣素基因相關胜肽（ａｎｔｉ-ｃｇｒｐ）組成物及其用途
CN103702685B (zh) 2011-05-20 2017-12-15 奥尔德生物控股有限责任公司 抗cgrp抗体和抗体片段用于在有需要的受试者、尤其是偏头痛患者中预防或抑制畏光或厌光的用途
KR102128628B1 (ko) 2011-05-20 2020-06-30 앨더바이오 홀딩스 엘엘씨 설사의 만성 및 급성 형태를 치료 또는 예방하기 위한 항-cgrp 또는 항-cgrp-r 항체 또는 항체 단편의 용도
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
RS65360B1 (sr) 2014-03-21 2024-04-30 Teva Pharmaceuticals Int Gmbh Antagonistička antitela specifična za peptid genski srodan kalcitoninu i postupci njihove upotrebe
AU2017331593B2 (en) 2016-09-23 2022-04-28 Teva Pharmaceuticals International Gmbh Treating refractory migraine
JP7472116B2 (ja) 2018-11-19 2024-04-22 ジャズ ファーマシューティカルズ アイルランド リミテッド 耐アルコール性製剤
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
SG10202003296VA (en) 2020-04-06 2021-11-29 H Lundbeck As Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656295A (en) * 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
CN1494907A (zh) * 1996-03-25 2004-05-12 治疗疼痛的药物组合物
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6992193B2 (en) * 2003-06-10 2006-01-31 Adolor Corporation Sulfonylamino phenylacetamide derivatives and methods of their use

Also Published As

Publication number Publication date
RS51069B (sr) 2010-10-31
KR20200128451A (ko) 2020-11-12
DK200700207U3 (da) 2007-09-28
CN101106996B (zh) 2013-10-23
KR20120089710A (ko) 2012-08-13
HK1107933A1 (en) 2008-04-25
UA85471C2 (ru) 2009-01-26
CA2595043C (en) 2013-11-19
MY144471A (en) 2011-09-30
DK200700207U1 (da) 2007-08-24
US20080200493A1 (en) 2008-08-21
KR20230170811A (ko) 2023-12-19
NO338968B1 (no) 2016-11-07
ATE446092T1 (de) 2009-11-15
US9271974B2 (en) 2016-03-01
NO20074174L (no) 2007-10-17
ES2333901T3 (es) 2010-03-02
KR20070100368A (ko) 2007-10-10
PT1838318E (pt) 2009-12-15
EP1838318B1 (en) 2009-10-21
US20150190393A1 (en) 2015-07-09
DE602006009899D1 (de) 2009-12-03
SI1838318T1 (sl) 2010-02-26
ME01066B (me) 2012-10-20
IL184530A0 (en) 2007-10-31
KR20170021905A (ko) 2017-02-28
MX2007007207A (es) 2007-08-15
NZ555852A (en) 2010-01-29
TWI432196B (zh) 2014-04-01
EA200701541A1 (ru) 2008-02-28
HRP20090679T1 (hr) 2010-01-31
AP2007004057A0 (en) 2007-08-31
AT9895U1 (de) 2008-05-15
KR20190135557A (ko) 2019-12-06
CA2595043A1 (en) 2006-07-27
EP1838318A1 (en) 2007-10-03
CY1109660T1 (el) 2014-08-13
KR20080106991A (ko) 2008-12-09
WO2006077212A1 (en) 2006-07-27
AU2006207498A1 (en) 2006-07-27
AP2249A (en) 2011-07-18
DE202006019887U1 (de) 2007-07-26
IL184530A (en) 2015-01-29
AR052880A1 (es) 2007-04-11
CN101106996A (zh) 2008-01-16
JP2008526927A (ja) 2008-07-24
BRPI0606247A2 (pt) 2009-06-09
AU2006207498B2 (en) 2009-11-19
JP5049139B2 (ja) 2012-10-17
PL1838318T3 (pl) 2010-03-31
ZA200705231B (en) 2008-06-25
KR20220165797A (ko) 2022-12-15
KR20140091782A (ko) 2014-07-22
TW200637554A (en) 2006-11-01
KR20210131450A (ko) 2021-11-02
EA013544B1 (ru) 2010-06-30

Similar Documents

Publication Publication Date Title
DE602005027052D1 (de) Endoskopbehandlungssystem
DK2409728T3 (da) System til ultralydsbehandling af væv
SMAP200900085A (it) 3-imidazolil-indoli per il trattamento di malattieproliferative
DK2117525T3 (da) Anvendelse af 1-phenyl-3-dimethylamino-propanforbindelser til behandling af neuropatismerte
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
ZA200705231B (en) Use of oxycodone for treating visceral pain
HUE054495T2 (hu) Rák kezelésére szolgáló készítmény
EP1854415A4 (en) SURGICAL TREATMENT DEVICE
CY2200156T2 (el) Επεξεργασια λυματων
DK1928438T3 (da) Anvendelse af ibudilast til behandling af stofafhængighed
NO20070251A (no) Brønnbehandling
NO20070297A (no) Brønnbehandling
DK1685834T3 (da) Anvendelse af pinolensyre til behandling af obesitet
DK3403657T3 (da) Anvendelse af oligouronater til behandling af slimhyperviskositet
DK1863899T3 (da) Hudbehandlingspræparater
EP1968591A4 (en) TREATMENT OF SYNUCLEINOPATHIES
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
PL1890705T3 (pl) Zastosowanie 24-nor-UDCA do leczenia cholestatycznych chorób wątroby
DK3332789T3 (da) Cladribinkur til behandling af multipel sklerose
FI20051207A0 (fi) Selän hoitolaite
EP1878443A4 (en) THERAPEUTIC AGENT AGAINST NEUROPATHIC PAIN
GB0602857D0 (en) The treatment of sialorrhoea
GB0412262D0 (en) Use of compounds for the treatment of pain
GB0500024D0 (en) The treatment of pre-term labour
GB0518003D0 (en) Treatment of hepatatis c